AI summary by TwinMind
How We Cured Hepatitis C
Asianometry
21m 54s
Historical Background of Hepatitis
- Hepatitis = liver inflammation, known since antiquity
- Sumerian clay tablet 5000 years ago: epidemic jaundice causing death in 11 days
- Sumerians blamed demon "Aku Kazu"
- Greeks/Romans reported epidemic jaundice outbreaks
- American Civil War: 40,000-50,000 cases
- 1885: Dr. Lerman noticed pattern - jaundice 1-7 months after smallpox vaccine
- 1942: 56,000 US Navy members infected from contaminated yellow fever vaccine
- Confirmed infectious agent existence
Classification of Hepatitis Types
- Split into two categories:
- Hepatitis A: epidemic version, short incubation, fecal-oral transmission, acute/fatal
- Hepatitis B: serum version, long incubation, needle/sexual transmission, chronic infection/liver failure/cancer
Discovery of Hepatitis B
- 1963: Barrack Bloomberg (NIH geneticist) mixed hemophiliac + Australian Aboriginal serums
- Created red stain, called "Australia antigen"
- HBS antigen discovery led to first hepatitis B vaccine
- Bloomberg won Nobel Prize share 1976
Discovery of Hepatitis A
- October 1973: Stephen Feinstone, Albert Capuchin, Robert Purcell (NIH)
- Identified virus in stool sample from jaundiced volunteer
- Published in Science weeks later
- Tests for both A & B available by 1974
Discovery of Non-A Non-B Hepatitis
- Despite A & B screening, post-transfusion hepatitis only decreased 20-25%
- Third form identified: "Non-A Non-B" hepatitis
- 15-year search for virus (initially thought would be quickly found)
- More dangerous than initially thought: chronic, causes liver failure/cancer
- Challenges: no defined antigen, no distinct appearance, wouldn't grow outside body
- Virus characteristics: 40-60 nanometers, inactivated by chloroform/heat
Early Treatment Attempts
- Blood screening: elevated ALT (alanine transaminase) levels indicating liver damage
- 1986 pilot study: interferon therapy showed improvements over 12 months
- Brought ALT levels to normal with minimal relapses
- First workable treatment for non-A non-B hepatitis
Breakthrough Discovery at Chiron
- 1982: Dr. Michael Houghton joined Chiron (California)
- Methods attempted:
- Built cDNA library from infected patients/chimps
- Screened against known virus types (flavavirus, togavirus, HEPA DNA viruses)
- Tried electron microscopy, cell culture growth
- Immunofluorescence, immunoelectrophoresis, radio immunoassays
- Late 1985: immunoscreening approach (against scientific panel advice)
- Used liver samples from infectious chimpanzee
- Created cDNA library, inserted into bacteria
- Screened ~1 million clone proteins against patient antibodies
- Quin-Lim Choo (Singaporean team member) found 5 positive clones
- 2 from virus, 2 from chimp genome, 1 unique (labeled "5-1-1")
- Fragment 5-1-1: 1,500 base pairs, neither human nor chimp
- Found only in non-A non-B hepatitis samples
- Led to complete genome sequencing and working antibody test
Hepatitis C Virus Characteristics
- Size: 65 nanometers wide, flavavirus family
- Structure: single RNA strand (~9,600 bases) + protein envelope
- Confused with lipid particles (cholesterol carriers)
- Very low viral load in humans
- Only 20% infected show symptoms
- Targets hepatocytes (liver cells)
- Key proteins: NS3, 4A, S4B, NS5A, NS5B (essential for replication)
- High mutation rate: up to 33% difference between variants
Global Impact
- 130-180 million people infected worldwide (2-3% global population)
- Highest rates: Middle East, Africa (Egypt, Cameroon), Asia (Pakistan, Taiwan)
- US: ~3 million infected (most before virus discovery)
- Transmission: primarily contaminated needles
- 23% new US infections, 33% deaths from injection drug use
- 75-85% won't clear virus without treatment
- 20% develop cirrhosis after 10-15 years
- 20x higher liver cancer risk
- Fastest rising cause of cancer deaths in US
Treatment Evolution
Early Treatments (1986-1998)
- Interferon therapy: <40% cure rate, unpleasant side effects
- 1998: Added ribavirin (antiviral for hemorrhagic fever viruses)
- Dual therapy: 40% cure rate (vs 0% interferon alone)
- Up to 80% cure rates depending on genetic strain
- Average ~50% effectiveness
- Adverse effects: rash, anemia, severe infections (40% chance in advanced disease)
Direct Acting Antivirals (DAAs)
- Concept: target specific viral proteins (like antibiotics for bacteria)
- Challenge: couldn't grow virus in culture, only infected chimpanzees
- 2001: New cell cultures and mutant mice introduced
- Focus on protease inhibitors (successful with HIV)
- NS3-4A protease: cuts polyprotein into functional pieces
- Performs 4 of 5 essential cuts
First Generation DAAs (2011)
- Boceprevir and Telaprevir approved May 2011
- 65-75% cure rate
- Issues: HIV co-infection complications, viral resistance (45% population in some areas)
- Incivek generated $1.6 billion revenue first year
Sofosbuvir Development
- Originally PSI-7977 by Pharmasset (2010)
- Named after study group leader Michael Sofia
- Predecessor PSI-6130: effective in lab, poor oral absorption
- Solution: prodrug that converts to active ingredient in liver
- Mechanism: binds NS5B protein, terminates RNA replication chain
- Effective against multiple genotypes, low toxicity, less resistance
Clinical Success
- Electron study: 100% effectiveness with ribavirin
- 2011: Gilead purchased Pharmasset for $11 billion (risky bet - 1/3 Gilead's market value)
- December 2013: FDA unanimous accelerated approval as breakthrough drug
- Sovaldi became fastest-selling drug launch at time
- 2014: $10 billion revenue ($12.5 billion with Harvoni combination)
- Sales peaked 2015, then declined as patients cured
Recognition and Current Status
- 2020 Nobel Prize: Michael Houghton, Harvey Alter, Charles Rice
- Dr. Quin-Lim Choo (original discoverer) not included in Nobel
- Hong Kong tycoon Li Ka-shing donated monetary sum to him
- Millions still infected worldwide
- Price controversy continues
- Vaccine development remains elusive for complete eradication
